20230821-招银国际-康德莱医械-01501.HK-Rapid_sales_recovery_in_1H23_6页_1mb

报告摘要

1H23 Revenue Growth: 509% year-on-year to RMB 340mn, driven by rapid recovery in interventional surgery demand post-COVID-19.
Profitability: Blended gross profit margin (GPM) improved by 39ppt to 59%, attributable net profit surged 583% YoY to RMB 81mn, with interventional devices contributing 571% growth and a 2ppt GPM increase to 65%.
Distribution Network: Expanded to 2,650 domestic hospitals (650 more than 2022) and covered 226 overseas customers in 66 countries; overseas revenue up 652% YoY to RMB 72mn, accounting for 21% of sales.
Financial Metrics: Analysts project 45% revenue growth in 2023E and 31% for 2024E; DCF valuation revised to HK$3330 target price, representing a 236% upside from the current level.

Product Portfolio: Strengthened with four new NMPA registrations (e.g., sinus implant, reperfusion catheters) and increased R&D expense to 19% in 1H23.
Long-term Growth: Enhanced pipeline for cardiovascular/neurological interventions; PCI surgery volumes expected to grow by 25% YoY in 2023, driving device sales.
R&D Progress: Consistently progressing device development with 19% R&D rate in 1H23, supporting future growth.

Analyst Rating: CMBIGM assigned a BUY rating based on strong, outperforming expected returns.
Valuation Factors: Target price HK$3330; upside driven by revenue projections but risks include provincial VBPs limiting profitability and margin compression.
Stock Price Performance: Current trading suggests potential upside, with long-term targets supported by DCF models; sensitivity analysis accounts for WACC and terminal growth rate variations.

Revenue: 1H23 reached RMB 340mn, with a 45% YoY growth projection for 2023E.
Profitability: Notable margins improving, but provincial VBPs may impact margins despite overallPCI growth.
Key Metrics: Elevated gross margin at 59% in 1H23; ROE projected at 161% by 2025E.

展开完整摘要